GnRH agonists, when given continuously and at high doses, desensitize pituitary GnRH-R, thus suppressing gonadal steroid secretion; on the basis of their activity, these compounds represent the most widely and successfully utilized medical treatment for androgen-responsive prostate cancer [2], [11]. This evidence concerns the gene GNRH1 and Familial prostate cancer.